| [1] |
Bend EG, Aref-Eshghi E, Everman DB, et al. Gene domain-specific DNA methylation episignatures highlight distinct molecular entities of ADNP syndrome[J]. Clin Epigenetics, 2019, 11(1): 64.
|
| [2] |
Gozes I, Morimoto BH, Tiong J, et al. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP)[J]. CNS Drug Rev, 2005, 11(4): 353-368.
|
| [3] |
Mollinedo P, Kapitansky O, Gonzalez-Lamuño D, et al. Cellular and animal models of skin alterations in the autism-related ADNP syndrome[J]. Sci Rep, 2019, 9(1): 736.
|
| [4] |
Pescosolido MF, Schwede M, Johnson Harrison A, et al. Expansion of the clinical phenotype associated with mutations in activity-dependent neuroprotective protein[J]. J Med Genet, 2014, 51(9): 587-589.
|
| [5] |
Vandeweyer G, Helsmoortel C, Van Dijck A, et al. The transcriptional regulator ADNP links the BAF (SWI/SNF) complexes with autism[J]. Am J Med Genet C Semin Med Genet, 2014, 166c(3): 315-326.
|
| [6] |
Deciphering Developmental Disorders Study. Large-scale discovery of novel genetic causes of developmental disorders[J]. Nature, 2015, 519(7542): 223-228.
|
| [7] |
Takenouchi T, Miwa T, Sakamoto Y, et al. Further evidence that a blepharophimosis syndrome phenotype is associated with a specific class of mutation in the ADNP gene[J]. Am J Med Genet A, 2017, 173(6): 1631-1634.
|
| [8] |
Krajewska-Walasek M, Jurkiewicz D, Piekutowska-Abramczuk D, et al. Additional data on the clinical phenotype of Helsmoortel-Van der Aa syndrome associated with a novel truncating mutation in ADNP gene[J]. Am J Med Genet A, 2016, 170(6): 1647-1650.
|
| [9] |
Gozes I, Patterson MC, Van Dijck A, et al. The eight and a half year journey of undiagnosed AD: gene sequencing and funding of advanced genetic testing has led to hope and new beginnings[J]. Front Endocrinol (Lausanne), 2017, 8: 107.
|
| [10] |
Du X, Gao X, Liu X, et al. Genetic diagnostic evaluation of Trio-based whole exome sequencing among children with diagnosed or suspected autism spectrum disorder[J]. Front Genet, 2018, 9: 594.
|
| [11] |
Huynh MT, Boudry-Labis E, Massard A, et al. A heterozygous microdeletion of 20q13.13 encompassing ADNP gene in a child with Helsmoortel-van der Aa syndrome[J]. Eur J Hum Genet, 2018, 26(10): 1497-1501.
|
| [12] |
Shillington A, Pedapati E, Hopkin R, et al. Early behavioral and developmental interventions in ADNP-syndrome: a case report of SWI/SNF-related neurodevelopmental syndrome[J]. Mol Genet Genomic Med, 2020, 8(6): e1230.
|
| [13] |
Grigg I, Ivashko-Pachima Y, Hait TA, et al. Tauopathy in the young autistic brain: novel biomarker and therapeutic target[J]. Transl Psychiatry, 2020, 10(1): 228.
|
| [14] |
Gale MJ, Titus HE, Harman GA, et al. Longitudinal ophthalmic findings in a child with Helsmoortel-Van der Aa syndrome[J]. Am J Ophthalmol Case Rep, 2018, 10: 244-248.
|
| [15] |
Pascolini G, Agolini E, Majore S, et al. Helsmoortel-Van der Aa syndrome as emerging clinical diagnosis in intellectually disabled children with autistic traits and ocular involvement[J]. Eur J Paediatr Neurol, 2018, 22(3): 552-557.
|
| [16] |
Alkhunaizi E, Walkiewicz MA, Chitayat D. Mutation in the ADNP gene associated with Noonan syndrome features[J]. Clin Dysmorphol, 2018, 27(2): 53-57.
|
| [17] |
Levine J, Cohen D, Herman C, et al. Developmental phenotype of the rare case of DJ caused by a unique ADNP gene De novo mutation[J]. J Mol Neurosci, 2019, 68(3): 321-330.
|
| [18] |
Abe-Hatano C, Iida A, Kosugi S, et al. Whole genome sequencing of 45 Japanese patients with intellectual disability[J]. Am J Med Genet A, 2021, 185(5): 1468-1480.
|
| [19] |
Van Dijck A, Vulto-van Silfhout AT, Cappuyns E, et al. Clinical presentation of a complex neurodevelopmental disorder caused by mutations in ADNP[J]. Biol Psychiatry, 2019, 85(4): 287-297.
|
| [20] |
Breen MS, Garg P, Tang L, et al. Episignatures stratifying helsmoortel-Van Der Aa syndrome show modest correlation with phenotype[J]. Am J Hum Genet, 2020, 107(3): 555-563.
|
| [21] |
Arnett AB, Rhoads CL, Hoekzema K, et al. The autism spectrum phenotype in ADNP syndrome[J]. Autism Res, 2018, 11(9): 1300-1310.
|
| [22] |
Helsmoortel C, Vulto-van Silfhout AT, Coe BP, et al. A SWI/SNF-related autism syndrome caused by de novo mutations in ADNP[J]. Nat Genet, 2014, 46(4): 380-384.
|
| [23] |
Siper PM, Layton C, Levy T, et al. Sensory reactivity symptoms are a core feature of ADNP syndrome irrespective of autism diagnosis[J]. Genes (Basel), 2021, 12(3): 351.
|
| [24] |
孙萌,娄燕,王鑫,等. Helsmoortel-Van der Aa综合征1例并文献复习[J].重庆医学, 2020, 49(5): 739-742.
|
| [25] |
李辉,潘黎明,戚锋锋. ADNP基因变异导致Helsmoortel-van der Aa综合征1例[J].中国优生与遗传杂志, 2021, 29(8): 1133-1136.
|
| [26] |
马健,马海霞,张开慧,等.一例Helsmoortel-van der Aa综合征患儿的ADNP基因变异分析[J].中华医学遗传学杂志, 2022, 39(4): 428-432.
|
| [27] |
Gozes I, Ivashko-Pachima Y, Sayas CL. ADNP, a microtubule interacting protein, provides neuroprotection through end binding proteins and tau: an amplifier effect[J]. Front Mol Neurosci, 2018, 11: 151.
|
| [28] |
Cappuyns E, Huyghebaert J, Vandeweyer G, et al. Mutations in ADNP affect expression and subcellular localization of the protein[J]. Cell Cycle, 2018, 17(9): 1068-1075.
|
| [29] |
Oz S, Kapitansky O, Ivashco-Pachima Y, et al. The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins[J]. Mol Psychiatry, 2014, 19(10): 1115-1124.
|
| [30] |
Vulih-Shultzman I, Pinhasov A, Mandel S, et al. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model[J]. J Pharmacol Exp Ther, 2007, 323(2): 438-449.
|
| [31] |
Morimoto BH, Schmechel D, Hirman J, et al. A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment[J]. Dement Geriatr Cogn Disord, 2013, 35(5-6): 325-336.
|
| [32] |
Morimoto BH, Fox AW, Stewart AJ, et al. Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases[J]. Expert Rev Clin Pharmacol, 2013, 6(5): 483-502.
|